New indication for AZ’s checkpoint antibody

AstraZeneca Plc has won a new indication for its checkpoint antibody Imfinzi (durvalumab) from the US Food and Drug Administration to reduce the risk of non-small cell lung cancer progressing. Imfinzi targets the programmed death ligand-1 (PD-L1).

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United States